Johnson & Johnson (NYSE:JNJ) Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 75.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,233 shares of the company’s stock after selling 50,440 shares during the period. International Assets Investment Management LLC’s holdings in Johnson & Johnson were worth $2,777,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of JNJ. Marathon Capital Management raised its holdings in Johnson & Johnson by 4.6% in the 3rd quarter. Marathon Capital Management now owns 27,264 shares of the company’s stock valued at $4,404,000 after acquiring an additional 1,200 shares during the last quarter. Castle Rock Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 3.9% during the 4th quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock worth $2,119,000 after buying an additional 479 shares during the last quarter. Blueshift Asset Management LLC increased its holdings in shares of Johnson & Johnson by 671.9% during the 3rd quarter. Blueshift Asset Management LLC now owns 30,365 shares of the company’s stock worth $4,904,000 after buying an additional 26,431 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 42.1% during the 3rd quarter. Pallas Capital Advisors LLC now owns 68,839 shares of the company’s stock worth $11,363,000 after buying an additional 20,404 shares during the last quarter. Finally, Achmea Investment Management B.V. increased its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Achmea Investment Management B.V. now owns 240,368 shares of the company’s stock worth $38,819,000 after buying an additional 3,829 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

In related news, insider William Hait sold 29,699 shares of the stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now owns 80,236 shares in the company, valued at $14,729,724.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Thibaut Mongon sold 23,681 shares of the stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

JNJ has been the subject of a number of research analyst reports. Bank of America initiated coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating for the company. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Citigroup upped their price target on shares of Johnson & Johnson from $203.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, April 20th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 30th. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $188.57.

NYSE:JNJ traded down $1.02 on Friday, reaching $176.85. The stock had a trading volume of 7,732,163 shares, compared to its average volume of 7,745,147. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company has a 50-day moving average of $177.92 and a 200 day moving average of $170.40. The stock has a market cap of $465.36 billion, a P/E ratio of 23.83, a price-to-earnings-growth ratio of 2.91 and a beta of 0.66. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. During the same quarter last year, the company posted $2.59 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.2 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be given a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date is Monday, May 23rd. This represents a $4.52 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.14%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.